[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Heidelberg Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":110},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,63,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100644525","phase-3-gmmg-hd11dsmm-xxi64007957mmy3010-100644525",false,"NCT07671287","GMMG-HD11\u002FDSMM XXI\u002F64007957MMY3010","Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients","AugMMent","Inclusion Criteria:\n\n1. 18 to 70 years of age, inclusive.\n2. Documented MM as defined by the criteria below:\n\n   1. MM diagnosis according to IMWG diagnostic criteria (Appendix 3),\n   2. Untreated MM requiring systemic therapy,\n   3. Measurable disease at screening, as defined by any of the following:\n\n   i. Serum M-protein level ≥1.0 g\u002FdL (central laboratory); or ii. Urine M-protein level ≥200 mg\u002F24 hours (central laboratory); or iii. Serum immunoglobulin free light chain ≥10 mg\u002FdL (central laboratory) and abnormal serum immunoglobulin kappa lambda free light chain ratio.\n3. Have an ECOG performance status 0-2 (Appendix 5) at screening and immediately prior to the start of administration of study treatment.\n4. Have clinical laboratory values meeting the following criteria during the screening period. Refer to Section 5.4.3 for criteria prior to first dose.\n\n   Hemoglobin ≥7.5 g\u002FdL (≥4.65 mmol\u002FL; without prior RBC transfusion ≤7 days before the screening laboratory test; recombinant human erythropoietin use is permitted). Platelets ≥75×109\u002FL in participants in whom \\\u003C50% of bone marrow nucleated cells are plasma cells and ≥50×109\u002FL in participants in whom ≥50% of bone marrow nucleated cells are plasma cells. Absolute neutrophil count ≥1.0×109\u002FL (prior growth factor support is permitted but must be without support for ≥7 days for G-CSF or GM-CSF and ≥14 days for pegylated-G-CSF) before the screening laboratory test.\n\n   Chemistry:\n\n   AST and ALT ≤3×ULN. Total bilirubin Total bilirubin ≤2.0×ULN; except in participants with congenital bilirubinemia, such as Gilbert syndrome (in which case if total bilirubin is \\>2.0×ULN, then direct bilirubin ≤1.5×ULN is required).\n\n   eGFR ≥30 mL\u002Fmin based on Cockcroft-Gault formula or creatine clearance measured by a 24-h urine collection. Serum calcium corrected for albumin ≤14 mg\u002FdL (≤3.5 mmol\u002FL) or free ionized calcium ≤6.5 mg\u002FdL (≤1.6 mmol\u002FL; see Appendix 10).\n5. Eligible for HD melphalan and ASCT (in the opinion of the investigator).\n6. A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test at screening and again either a serum or urine pregnancy test within 24 hours of the start of study treatment and must agree to further serum or urine pregnancy tests during the study.\n7. A female participant must be (as defined in Appendix 1):\n\n   1. Not of childbearing potential, or\n   2. Of childbearing potential and practicing at least 1 highly effective method of contraception\n8. A female participant must agree not to donate eggs (ova, oocytes) or freeze for future use, for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study treatment. Female participants should consider preservation of eggs prior to study treatment because anticancer treatments may impair fertility.\n9. A male participant must wear a condom (with or without spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) when engaging in any activity that allows for\n10. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for 3 months after receiving the last dose of study treatment. Male participants should consider preservation of sperm prior to study treatment as anticancer treatments may impair fertility.\n11. Must agree to abstain from donating blood while taking lenalidomide and for 28 days following discontinuation of lenalidomide therapy.\n12. Must sign an ICF indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study.\n13. Must be willing and able to adhere to the lifestyle restrictions specified in this protocol\n\nExclusion Criteria:\n\n1. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM).\n2. Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy.\n3. Any active malignancy (ie, progressing or requiring treatment change in the last 24 months) other than MM. The only allowed exceptions are malignancies treated within the last 24 months that are considered cured:\n\n   1. Nonmuscle invasive bladder cancer (solitary Ta-PUN-LMP or low grade, \\\u003C3 cm, no carcinoma in situ).\n   2. Nonmelanoma skin cancers treated with curative therapy or localized melanoma treated with curative surgical resection alone.\n   3. Noninvasive cervical cancer.\n   4. Breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ or history of localized breast cancer (antihormonal therapy is permitted).\n   5. Localized prostate cancer (M0, N0) with a Gleason Score ≤7a, treated locally only (radical prostatectomy\u002Fradiation therapy\u002Ffocal treatment).\n   6. Other malignancy that is considered cured with minimal risk of recurrence in consultation with the sponsor's medical monitor.\n4. Plasma cell leukemia (presence of ≥5% circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic MM; Fernández de Larrea 2021), smoldering MM, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), primary light chain amyloidosis.\n5. CNS involvement or clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain MRI and lumbar cytology are required to exclude CNS involvement.\n6. Prior BCMA-directed therapy.\n7. Prior T-cell redirection therapy.\n8. History of allogeneic or autologous stem cell transplant or prior organ transplant.\n9. Prior or concurrent exposure to any of the following within the specified timeframe prior to randomization:\n\n   1. Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 21 days or ≥5 half-lives, whichever is less.\n   2. Investigational vaccine within 4 weeks.\n   3. Monoclonal antibody therapy within 21 days.\n   4. Radiotherapy within 14 days or focal radiation within 7 days.\n10. Received a cumulative dose of corticosteroids equivalent to dexamethasone ≥160 mg within 14 days before treatment randomization (see Appendix 7).\n11. Received a live, attenuated vaccine within 4 weeks before the first dose of study treatment. Nonlive or nonreplicating vaccines authorized for emergency use (eg, COVID-19) by local health authorities are allowed.\n12. Participant had major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment.\n13. Concurrent medical or psychiatric condition or disease that is likely to interfere with study procedures or results, ie, those listed below, or any others that in the opinion of the investigator would constitute a hazard for participating in the study.\n\n    1. Acute diffuse infiltrative pulmonary disease.\n    2. Evidence of active systemic viral, fungal, or bacterial infection, requiring systemic antimicrobial therapy.\n    3. Active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment. Exception: Participants with vitiligo, controlled type I diabetes, and prior autoimmune thyroid disease that is currently euthyroid based on clinical symptoms and laboratory testing are eligible regardless of when these conditions were diagnosed.\n    4. Disabling psychiatric conditions (eg, alcohol or drug abuse), severe dementia, or altered mental status.\n    5. Any other issue that would impair the ability of the participant to receive or tolerate the planned treatment at the study site, to understand informed consent or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.\n    6. History of noncompliance with recommended medical treatments.\n14. Stroke, transient ischemic attack, or seizure within 6 months prior to randomization.\n15. Any of the following:\n\n    1. Seropositive for human immunodeficiency virus (HIV).\n    2. Hepatitis B infection (ie, positive HBsAg or detectable HBV DNA levels by RTPCR).\n\n       In the event the infection status is unclear, quantitative viral levels are necessary to determine the infection status see Section 6.8.2.8 for further required assessments.\n    3. Active hepatitis C infection as measured by detectable HCV RNA. Participants with a history of HCV antibody positivity must undergo HCV RNA testing. If a participant with history of chronic hepatitis C infection (defined as both HCV antibody and HCV RNA positive) completed antiviral therapy and has undetectable HCV RNA 12 weeks following the completion of therapy, the participant is eligible for the study.\n    4. COPD with a FEV1 \\\u003C50% of predicted normal. Note that FEV1 testing is required for participants with known or suspected of having COPD or asthma and participants must be excluded if FEV1 \\\u003C50% of predicted normal.\n    5. Moderate or severe persistent asthma within the past 2 years (see Appendix 8), or uncontrolled asthma of any classification. Note that FEV1 testing is required for participants known or suspected asthma and participants must be excluded if FEV1 \\\u003C50% of predicted normal.\n16. Presence of the following cardiac conditions:\n\n    1. New York Heart Association stage III or IV congestive heart failure (Appendix 12).\n    2. Myocardial infarction, unstable angina, or coronary artery bypass graft\n\n       ≤6 months prior to enrollment.\n    3. History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration.\n    4. Uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities.\n17. Participant is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment.\n18. Participant plans to father a child while enrolled in this study or within 3 months after the last dose of study treatment.\n19. History of hypersensitivity to study intervention or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.\n20. Participation in other clinical studies or observation period of competing clinical studies, respectively.\n21. Held in an institution by legal or official order.\n22. Legally incapacitated.","ALL","18 Years","70 Years",{"count":21,"type":22},399,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This is an open-label, randomized interventional multicenter Phase 3 clinical trial to investigate the efficacy and safety of Tec-DRd induction therapy and fixed-duration Tec-D maintenance post ASCT in adult participants with TE NDMM, compared with the SoC PERSEUS regimen.\n\nA total of 399 participants with TE NDMM aged ≥18 and ≤70 years and an Eastern CooperativeOncology Group (ECOG) status 0-2 will be included.\n\nThe primary objective of the clinical trial:\n\nTo determine the efficacy of Tec-DRd compared to DVRd after 6 cycles of induction\u002Fconsolidation therapy and HD melphalan and ASCT, before start of maintenance therapy in participants with TE NDMM.\n\nEndpoint: Cumulative MRD negativity by NGS at a sensitivity level of 10-6 before start of maintenance therapy.",[28],"Multiple Myeloma","NOT_YET_RECRUITING","2026-06-22",{"date":32,"type":33},"2026-06-26","ACTUAL",{"date":35,"type":22},"2026-06-30",{"date":37,"type":22},"2033-01-30",{"name":39,"class":40},"University of Heidelberg Medical Center","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100532696","phase-3-iberdomide-vs-iberdomide-plus-isatuximab-maintenance-therapy-post-asct-in-newly-diagnosed-multiple-myeloma-100532696","NCT06216158","Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma","A Randomized Phase III Trial Assessing Iberdomide Versus Iberdomide Plus Isatuximab Maintenance Therapy Post Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma","Inclusion Criteria:\n\n* Prior inclusion and treatment within the GMMG-HD8 \u002F DSMM XIX trial OR\n* Received a quadruplet induction\u002Fconsolidation therapy that consists of a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) \\[e.g., bortezomib, thalidomide and dexamethasone, or bortezomib, lenalidomide and dexamethasone\\] with an anti-CD38 monoclonal antibody (isatuximab or daratumumab)\n* Post HDM\u002FASCT consolidation containing similar substances as induction therapy is permitted\n* Induction and consolidation therapy should make up a total of at least 4 up to 6 cycles, with a maximum of 2 consolidation cycles post HDM\u002FASCT AND\n* Received at least one cycle high dose melphalan therapy (HDM) and autologous stem cell transplantation (ASCT)\n* At least Partial Response (PR) according to IMWG criteria at inclusion in the trial\n* Age of at least 18 years at trial inclusion\n* WHO performance status of 0, 1, or 2\n* Negative pregnancy test at inclusion (women of childbearing potential)\n* For all men and women of childbearing potential: patients must be willing and capable to use adequate contraception during the complete therapy\n* Ability of patient to understand character and individual consequences of the clinical trial\n* Written informed consent (must be available before enrolment in the trial)\n\nExclusion Criteria:\n\n* Subjects with gastrointestinal disease that may significantly alter the absorption of iberdomide\n* Patient has known hypersensitivity (or contraindication) to any of the components of study therapy that are not amenable to premedication with steroids or H1 blockers and that would prohibit further treatment with these agents (e.g. known intolerance or hypersensitivity to infused proteins products, sucrose, histidine, and polysorbate 80 as well as intolerance to arginine and Poloxamer 188)\n* Patients with a history of serious allergic reaction to another immunomodulatory agent (thalidomide, lenalidomide, or pomalidomide)\", as angioedema and severe dermatologic reactions, including Grade 4 rash and exfoliative or bullous rash\n* Patients currently being treated with strong inhibitors or inducers of CYP3A4\u002F5\n* Systemic AL amyloidosis (except for localized AL amyloidosis limited to the skin or the bone marrow), plasma cell leukemia or polyneuropathy, organomegaly, endocrinopathy, monoclonal-protein and skin abnormalities or Waldenström macroglobulinemia.\n* Previous systemic anti-myeloma treatment other than administered within the GMMG-HD8 \u002F DSMM XIX trial or other than defined in the inclusion criteria above (including up to two cycles cycle high dose melphalan therapy (HDM) and autologous stem cell transplantation (ASCT). Local, consolidative radiotherapy for myeloma disease is permitted unless performed in case of progressive disease according to IMWG criteria\n* Severe cardiac dysfunction (NYHA classification III-IV)\n* Significant hepatic dysfunction (ASAT and\u002For ALAT ≥ 3 times normal level and\u002For serum bilirubin ≥ 1.5 times normal level if not due to hereditary abnormalities as Gilbert's disease), unless related to MM or HDM\u002FASCT.\n* Patients with active or uncontrolled hepatitis B or C or detectable liver disease due to hepatitis B or C. In case of history of hepatitis B or C, it must be clarified whether it has been overcome and negative circulating HBV-DNA or HCV-RNA must be provided. Positive hepatitis B status may only be acceptable in absence of circulating HBV-DNA or signs of chronic or acute infection and if an adequate prophylaxis is being implemented during the course of the study. Prophylaxis for patients with history of hepatitis B or C should be set on a patient individual basis.\n* HIV positivity\n* Patients with active, uncontrolled infections\n* Patients with severe renal insufficiency (Creatinine Clearance \\\u003C 30ml\u002Fmin) or requiring hemodialysis\n* Patients with peripheral neuropathy or neuropathic pain, grade 2 or higher (as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE, version 5.0)\n* Patients with a history of any active malignancy during the past 5 years with the exception of following malignancies after curative therapy: basal cell carcinoma of the skin, squamous cell skin carcinoma, stage 0 cervical carcinoma or any in situ malignancy. A history of an early stage malignancy during the past 5 years may be acceptable, however, in this case the GMMG study office has to be consulted prior to study inclusion\n* Patients with acute diffuse infiltrative pulmonary and\u002For pericardial disease\n* Autoimmune haemolytic anaemia with positive indirect Coombs test or immune thrombocytopenia\n* Platelet count \\\u003C 75 x 109\u002Fl\n* Haemoglobin ≤ 8.0 g\u002Fdl, unless related to MM\n* Absolute neutrophil count (ANC) \\\u003C 1.0 x 109\u002Fl (the use of colony stimulating factors within 14 days before the test is not allowed)\n* Corrected serum calcium \\> 14 mg\u002Fdl (\\> 3.5 mmol\u002Fl)\n* Unable or unwilling to undergo thromboprophylaxis\n* Pregnancy and lactation\n* Participant has any concurrent severe and\u002For uncontrolled medical condition or psychiatric disease that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study or that confounds the ability to interpret data from the study\n* Subjects, who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities\n* Participation in other interventional clinical trials. This does not include long-term follow-up periods without active drug treatment of previous studies during the last 6 months.",{"count":49,"type":22},411,[25],"The goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen. The trial is the subsequent maintenance therapy to GMMG-HD8\u002FDSMM XIX trial for patients with newly-diagnosed multiple myeloma. Patients with newly-diagnosed multiple myeloma who underwent a similar quadruplet induction\u002Fconsolidation therapy regimen followed by at least one ASCT can also be recruited. The main question it aims to answer is:\n\n• Will the addition of isatuximab lead to decreased amounts of measurable myeloma cells in the bone marrow after two years?",[28],"RECRUITING","2026-01-29",{"date":56,"type":33},"2026-02-02",{"date":58,"type":33},"2024-04-05",{"date":60,"type":22},"2029-06",{"name":39,"class":40},69,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100492696","phase-2-gmmg-hd10--dsmm-xx--64007957mmy2003-majestec-5-100492696","NCT05695508","GMMG-HD10 \u002F DSMM-XX \u002F 64007957MMY2003, MajesTEC-5","A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants With Newly Diagnosed Transplant Eligible Multiple Myeloma","HD10\u002FDSMMXX","Inclusion Criteria:\n\n\\- 18 years of age to 70 years of age, inclusive\n\n* Have an ECOG performance status score of 0 to 2 at screening\n* Have an ECOG performance status score of 0 to 2 at screening and immediately prior to the start of administration of study treatment\n\nParticipants in Arms A, A1, B, D, E, E1, F, F1 and G must also satisfy all of the following criteria to be enrolled in the study:\n\n1\\. Documented multiple myeloma requiring treatment as defined by the criteria below:\n\n1. Multiple myeloma diagnosis according to the IMWG diagnostic criteria\n2. Measurable disease at screening as defined by any of the following:\n\n   1\\. Serum M-protein level ≥1.0 g\u002FdL or 2. Urine M-protein level ≥200 mg\u002F24 hours or 3. Serum immunoglobulin free light chain level ≥10 mg\u002FdL and abnormal serum free light chain ratio 2. Newly diagnosed participants for whom HDT and ASCT is part of the intended treatment plan (except Arm D and G participants).\n\n   Participants Arm C and C2 must also satisfy all of the following criteria:\n   1. Newly diagnosed multiple myeloma according to IMWG criteria.\n   2. Must have received 4 to 6 28-day cycles of 3 or 4 drug-induction therapy that includes a proteasome inhibitor and\u002For an IMiD with or without anti-CD38 monoclonal antibody and a single or tandem ASCT. Post-ASCT consolidation is permitted for up to 2 cycles as long as the total number of induction plus consolidation cycles does not exceed 6.\n\n   3 Must have received only one line of therapy and achieved at least a PR as per IMWG 2016 response criteria based on the investigator's assessment. Participants with plasmacytomas at the time of diagnosis must meet IMWG 2016 response criteria for ≥PR based on repeat imaging utilizing the same modality 4. Must have received HDT and ASCT within 12 months of the start of induction therapy and be within 6 months of the last ASCT (7 months for participants who received consolidation) at the time of enrollment.\n\n   Exclusion Criteria:\n\n   \\- CNS involvement or clinical signs of meningeal involvement of multiple myeloma.\n\n   \\- Stroke or seizure within 6 months prior study start Cycle1 Day1.\n\n   \\- History of transplantations requiring immunosuppressive therapy.\n\n   \\- Seropositive for HIV, HEP B, Active Hep C infection (details see protocol).\n\n   \\- COPD with a FEV1 \\\u003C50% of predicted normal.\n\n   \\- Moderate \u002Fsevere persistent asthma within the past 2 years or any uncontrolled asthma. Exclude if FEV1 \\\u003C50% of predicted normal.\n\n   \\- Concurrent medical or psychiatric condition or disease that is likely to interfere with study procedures, or that in the investigators opinion would constitute a hazard for participants.\n\n   \\- Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug\u002Fexcipients.\n\n   \\- Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of any study treatment regimen.\n\n   \\- Plans to father a child while enrolled in this study or within 100 days after the last dose of any component of the study treatment regimen.\n\n   Arm A, A1, B, D, E, E1, F, F1\n   * Prior or current systemic therapy or stem cell transplant for any plasma cell dyscrasia, with the exception of emergency use of a short course (equivalent of dexamethasone 40 mg\u002Fday for a maximum 4 days) of corticosteroids before treatment.\n   * Arm B only: Peripheral neuropathy or neuropathic pain Grade 2 or higher as defined by the NCI-CTCAE Version 5.\n\n   Due to a potential interaction with bortezomib, received a strong CYP3A4 inducer within 5 half-lives prior to enrollment\n\n   Arm C and C2\n\n   \\- Discontinued treatment due to any AE related to lenalidomide as determined by the investigator.\n   * Progressed on multiple myeloma therapy at any time prior to screening.\n   * Received a cumulative dose of corticosteroids equivalent to ≥40 mg of dexamethasone within the 14 day period before the start of study treatment administration.\n   * Intolerant to the starting dose of lenalidomide (10 mg).\n\n   For further details on inclusion\u002Fexclusion criteria please refer to the study protocol.",{"count":72,"type":22},160,[74],"PHASE2","A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma\n\nOBJECTIVES:\n\nTo evaluate the safety and tolerability of teclistamab-, talquetamab-, and JNJ-79635322-based combination regimens over the entire treatment phase for each arm, in participants with ND-TEMM\n\nTo evaluate the efficacy of teclistamab- and talquetamab-based combination regimens as induction and post-transplant maintenance treatments; JNJ-79635322-based combinations as induction and as replacement for HDT+ASCT following induction; and teclistamab in combination with talquetamab",[28],"2025-12-17",{"date":79,"type":33},"2025-12-24",{"date":81,"type":33},"2022-12-01",{"date":83,"type":22},"2029-09-15",{"name":39,"class":40},11,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},"100343562","evaluation-of-optical-coherence-tomography-in-dentistry-100343562","NCT03753256","Evaluation of Optical Coherence Tomography in Dentistry","Inclusion Criteria:\n\n* Orthodontic treatment need\n* Informed consent from all patients and their parents or legal guardians after explaining of the study\n\nExclusion Criteria:\n\n• withdrawn consent","6 Years",{"count":94,"type":22},20,[96],"NA","Optical coherence tomography (OCT) is a medical diagnostic tool, providing non-invasive, non-radiative and high resolution imaging. OCT has been established since many years in ophthalmology. In dentistry the diagnostic potential of OCT is currently increasingly being noticed. This clinical study includes two individual trials: (i) Longitudinal assessment of surface sealant thickness using optical coherence tomography and (ii) comparison of crevicular fluid levels of inflammatory cytokines after the application of surface sealants.",[99,100],"Dental Caries","Tooth Demineralization","2018-11-26",{"date":103,"type":33},"2018-11-28",{"date":105,"type":33},"2017-12-04",{"date":107,"type":22},"2027-12",{"name":39,"class":40},1,""]